CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced that Aoife Brennan, M.B.
Ch.B., Synlogic's president and chief executive officer, and other
members of the executive team will present at the following virtual
banking conferences:
- HC Wainwright 22nd Annual Global Investor
Conference: The Company will present at 12:00 noon on
Tuesday, September 15, 2020.
- Oppenheimer Fall Healthcare Life Sciences & Med Tech
Summit: The Company will present at 4.10 pm on Wednesday, September 23, 2020
- Jefferies IBD Therapeutics Summit: The Company will
present at a time to be determined on Wednesday, September 23, 2020.
These are virtual events. A live webcast of the presentations
can be accessed under "Event Calendar" in the Investors & Media
section of the Company's website. An archived copy of the webcast
will be available on the Synlogic website for approximately 30 days
after the event.
About Synlogic
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic therapeutics that target validated underlying
biology to treat disease in new ways. Synlogic's proprietary
pipeline includes Synthetic Biotics for the treatment of metabolic
disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria
(HOX). The company is also building a portfolio of partner-able
assets in immunology and oncology.
Forward-Looking Statements
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original
content:http://www.prnewswire.com/news-releases/synlogic-to-present-at-upcoming-virtual-banking-conferences-301125663.html
SOURCE Synlogic, Inc.